‘The New Economy’ Magazine Names SynCardia Best Medical Device Firm
for Best Medical Device Company The international quarterly publication, which covers topics of innovation worldwide, cites the SynCardia Total Artificial Heart because it saves patients dying from end-stage biventricular heart failure when they cannot get matching donor heart transplants in time. The SynCardia Heart provides the needed blood flow that helps patients recover and be in better condition for their matching donor heart transplants.
SynCardia Systems, Inc., earned the 2014 New Economy Award for Best Medical Device Company for its SynCardia Total Artificial Heart, which bridges patients dying from end-stage biventricular heart failure to donor heart transplants.
TUCSON, Ariz. – Oct. 15, 2014 – SynCardia Systems, Inc., which manufactures the world’s only FDA (United States), Health Canada and CE (Europe)-approved Total Artificial Heart, has won the 2014 New Economy Award for Best Medical Device Company.
The New Economy, a London-based quarterly publication that covers topics of innovation worldwide, announced the award to SynCardia in its recently released autumn 2014 issue, which also is available online. A listing of all winners by category will appear in its winter edition.
The annual awards “identify and celebrate companies that are achieving success and breaking new ground across technology, energy, business and strategy,” according to the magazine.
“The need for donor hearts is growing as end-stage heart disease continues to claim a greater percentage of the world’s population,” says Michael P. Garippa, SynCardia Systems CEO and President. “The SynCardia temporary Total Artificial Heart provides a life-saving bridge to transplant.”
According to the U.S. Department of Health & Human Services, about 4,000 people wait for a donor heart transplant on any given day, while the supply of approximately 2,300 donor hearts annually has been flat in the U.S. for over 20 years.
More than 1,350 SynCardia Total Artificial Hearts have provided more than 400 years of support for patients around the world who instead would have died because they could not get a donor heart in time.
Similar to a heart transplant, the SynCardia Total Artificial Heart is the only approved device that eliminates the source of end-stage biventricular heart failure in which the heart’s two ventricles can no longer pump enough blood for the patient to survive.
The company, based in Tucson, Arizona, also manufactures the Freedom® portable driver, which powers the SynCardia Heart. At 13.5 pounds, or about 6 kilos, it is light enough to be worn in a backpack, carried in a shoulder bag or wheeled on a cart.
The wearable Freedom portable driver allows clinically stable SynCardia Total Artificial Heart patients to be discharged from the hospital to wait for their matching donor hearts at home and in their communities. This eliminates most in-hospital costs for this portion of the patient’s care.
The Freedom portable driver provides nearly unlimited mobility, which allows patients to exercise, socialize, eat home-prepared meals and sleep in their own beds, all of which help the patient gain strength for their donor heart transplant.